Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
Name:
36482128.pdf
Size:
720.0Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Locatelli, F.Zugmaier, G.
Rizzari, C.
Morris, J. D.
Gruhn, B.
Klingebiel, T.
Parasole, R.
Linderkamp, C.
Flotho, C.
Petit, A.
Micalizzi, C.
Zeng, Y.
Desai, R.
Kormany, W. N.
Eckert, C.
Möricke, A.
Sartor, M.
Hrusak, O.
Peters, C.
Saha, Vaskar
Vinti, L.
von Stackelberg, A.
Affiliation
IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy.Issue Date
2022
Metadata
Show full item recordAbstract
NoneCitation
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia. 2022 Dec 8. PubMed PMID: 36482128. Epub 2022/12/10. eng.Journal
LeukemiaDOI
10.1038/s41375-022-01770-3PubMed ID
36482128Additional Links
https://dx.doi.org/10.1038/s41375-022-01770-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41375-022-01770-3
Scopus Count
Collections
Related articles
- Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
- Authors: Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, Zeng Y, Pilankar D, Morris J, von Stackelberg A
- Issue date: 2022 Aug
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
- Authors: Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS
- Issue date: 2024 Jul 25
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
- Authors: Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC
- Issue date: 2011 Jun 20
- Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.
- Authors: Hilal T, Prasad V
- Issue date: 2018 Dec
- Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
- Authors: Mikhailova E, Popov A, Roumiantseva J, Budanov O, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khachatryan L, Pshonkin A, Ponomareva N, Boichenko E, Varfolomeeva S, Dinikina J, Novichkova G, Henze G, Karachunskiy A
- Issue date: 2024 Jun 6